Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

  title={Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP},
  author={Gianni Bonadonna and Roberto Zucali and Silvio Monfardini and Mario de Lena and Carlo Uslenghi},
This paper reports the preliminary results of a controlled study randomizing MOPP vs. a new four‐drug combination (ABVD) in advanced Hodgkin's disease. ABVD consists of 6 cycles of adriamycin, bleomycin, vinblastine, and imidazole carboxamide. The purpose for designing this new combination was two‐fold: to compare the efficacy of ABVD with MOPP, and to demonstrate absence of cross‐resistance between the two regimens. Of 60 patients entered into the study, 45 (MOPP 25, ABVD 20) are presently… 

Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP)

The role for ABVD appears to be in conjunction with other regimens in the induction of patients with adverse features at presentation or during induction; or in the salvage and palliation of patients who demonstrate a response but fail to achieve remission, either initially or at relapse, with MOPP or MVPP.

Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease.

The overall and complete responses were fractionally inferior to the recently published hybrid MOPP/ ABV combination and that of ABVD chemotherapy and the disadvantages are absence of pulmonary toxicity, markedly lower incidence of sterility and nausea and vomiting.

Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy

ABVD was not an effective curative regimen for patients with Hodgkin's disease who have failed MOPP and two of the six CR patients have already relapsed.

Alternating drug combinations in the treatment of advanced Hodgkin's disease.

It is concluded than alternating non-cross-resistant combinations appear promising in the management of advanced Hodgkin's disease and are worthy of trial in other malignant diseases.

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

The early sequential rotation of two equally effective and non-cross-resistant drug combinations can substantially improve the likelihood of cure in patients with Hodgkin's disease.

Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)

ABVD appears a simple, effective, and tolerable multiple-drug chemotherapy for use in patients who are resistant to MOPP, and the results indicate that there is no cross-resistance between MOPp and ABVD.

Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy.

From this small population of children with HD it is concluded that treatment with MOPP/ABVD for 6 cycles without radiotherapy may be adequate and the occurrence of gonadal dysfunction may be less frequent than with 6 cycles of MopP.

ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease.

The ABVD regimen appears to be effective and well tolerated confirming the validity of this four-drug regimen in the treatment of advanced Hodgkin's disease.

Treatment of MOPP‐refractory Hodgkin‐s disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine

It is suggested that long‐term disease‐free survival and potential cure can be achieved with VABCD in MOPP‐refractory Hodgkin‐s disease.

Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease.

ABVD is an effective salvage regimen for MOPP-resistant Hodgkin's disease and 38% of patients who attained complete remission have remained alive and continuously disease free at 5 years from start of ABVD treatment.



A decade of combination chemotherapy of advanced Hodgkin's disease

The results of this combined drug program and of several other studies employing combinations of effective drugs consistently show a higher rate of induction of complete remissions in patients with advanced Hodgkin's disease and prolongation of remission duration after all therapy is stopped.

Combination chemotherapy with nitrogen mustard, vincristine, procarbazine and prednisone in previously treated patients with Hodgkin's disease.

Therapy was well tolerated, with leukopenia being the major dosage-limiting toxicity, and there was a progressively poorer tolerance to the drugs with increasing extent of prior radiotherapy.

Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma

The survival of patients with lymphosarcoma or reticulum cell sarcoma receiving COP treatment was significantly superior to a comparable group of patients treated sequentially with single agents.

Comparative Toxic and Therapeutic Effects of Adriamycin and Bleomycin in Malignant Lymphoma

Because of their toxic and therapeutic properties, both drugs appear suitable for therapeutic trials in combination with conventional agents.

Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide

Combination therapy with adriamycin and DIC appears to be an effective and promising regimen in the treatment of metastatic sarcomas.

Multiple chemotherapeutic agents for Hodgkin disease. Comparison of three routines: a cooperative study by acute leukemia group B.

Two hundred forty-seven patients with disseminated Hodgkin disease were randomly treated with one of three intensive multiple-agent regimens and the simultaneous dosage routine was superior in both response rate and lessened toxicity compared to sequential usage of the same drugs with the same total dosage.

MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients

A decreased duration of remission correlated with older age, the presence of systemic symptoms, and bone marrow involvement, as well as prior radiotherapy and prior chemotherapy.

A clinical review of bleomycin—a new antineoplastic agent

In conclusion, bleomycin appeared to be useful in the treatment of patients with specific tumors refractory to standard treatment and/or whose bone marrow status precluded the use of conventional chemotherapy.

Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy

Twenty one patients with Hodgkin's disease who were in relapse following extensive radiation therapy were treated with a combination chemotherapy program (MOPP), which included nitrogen mustard,